Efficacy of icotinib in lung squamous-cell cancer: A real-world experience from single institution
Jianping Xu1, Xiaoyan Liu1, Sheng Yang1
1Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Aim:
Squamous cell carcinoma is a less common type of nonsmall cell lung cancer (NSCLC) which associates with a poor clinical prognosis and lacks specific therapy. This study aimed to evaluate the efficacy and safety of icotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has proven to be effective in EGFR-mutated NSCLC, in patients with lung squamous-cell cancer.
Methods:
Retrospective analysis was conducted in patients who had advanced lung squamous-cell cancer confirmed by cytology or histology. Patients were treated orally with icotinib (125 mg, three times daily) until event of unacceptable toxicity, disease progression or death. The primary endpoint was overall survival. The secondary endpoints were progression-free survival, overall response rate and disease control rate.
Results:
Between January 2014 and May 2016, 20 patients were enrolled and evaluated for the efficacy and safety of icotinib. Overall, the median overall survival and progression-free survival were 9.93 months (95% confidence interval (CI): 3.46-16.40) and 3.0 months (95% CI: 0.00-8.35), respectively. The overall response rate and disease control rate were 20% and 70%, respectively. For treatment-naive patients (n = 11), the overall survival and progression-free survival were 9.93 months (95% CI: 0.00-23.49) and 6.27 months (95% CI: 0.00-12.61); the response rate and disease control rate were 27.3% and 54.5%, respectively. The overall survival and progression-free survival of patients treated with second- or multiple-line icotinib treatment (n = 9) were 6.5 months (95% CI: 0.80-12.20) and 1.2 months (95% CI: 1.10-1.30). A total of 11 patients experienced at least one treatment-related adverse event, most of which were mild to moderate. The most common manifestations were rash (n = 6, 30%) followed by diarrhea (n = 2, 10%).
Conclusion:
Icotinib has demonstrated a favorable efficacy and safety profile in patients with advanced lung squamous-cell cancer.
Insights
Icotinib shows promise for advanced lung squamous cell carcinoma, offering a median overall survival of 9.93 months. This study evaluated icotinib
Area of Science:
- Oncology
- Pharmacology
Background:
- Lung squamous cell carcinoma (LSCC) is a subtype of non-small cell lung cancer (NSCLC) with a poor prognosis and limited targeted therapies.
- Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have shown efficacy in EGFR-mutated NSCLC.
Purpose of the Study:
- To assess the efficacy and safety of icotinib, an EGFR-TKI, in patients with advanced lung squamous cell carcinoma.
- To evaluate overall survival, progression-free survival, overall response rate, and disease control rate in this patient population.
Main Methods:
- Retrospective analysis of 20 patients with advanced lung squamous cell carcinoma.
- Patients received oral icotinib (125 mg three times daily) until disease progression, unacceptable toxicity, or death.
- Primary endpoint was overall survival; secondary endpoints included progression-free survival, overall response rate, and disease control rate.
Main Results:
- Median overall survival was 9.93 months (95% CI: 3.46-16.40) and median progression-free survival was 3.0 months (95% CI: 0.00-8.35).
- Overall response rate was 20% and disease control rate was 70%.
- Treatment-related adverse events occurred in 11 patients, primarily mild to moderate rash and diarrhea.
Conclusions:
- Icotinib demonstrated a favorable efficacy and safety profile in patients with advanced lung squamous cell carcinoma.
- The study suggests icotinib as a potential therapeutic option for this patient group.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Related Concept Videos
02:34Inhibition of Cdk Activity
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...